Skip to Content

Bio-Rad Laboratories Inc Class A BIO Stock Quote

| Rating as of

Morningstar‘s Stock Analysis BIO

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Tough Comparables and Foreign Exchange Lead to Bio-Rad Sales Decline; Core Results Meet Expectations

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

While Bio-Rad’s second-quarter sales decline may seem disappointing, the story of the quarter was like the first quarter in that growth declines were not as bad as feared, and the company maintained margins in the face of inflation headwinds. Our $524 fair value estimate and narrow-moat ratings are unchanged, although we have slightly reduced our top-line forecasts for the year to account for foreign-exchange effects.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BIO

Company Profile BIO

Business Description

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

1000 Alfred Nobel Drive
Hercules, CA, 94547
T +1 510 724-7000
Industry Medical Devices
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 7,900